Referenser till artikeln "Profylax och behandling av Alzheimers sjukdom med farmakologisk nutrition"
av Paul R. Clayton

1. A. Wimo, B. Winblad et al., “An estimate of the total worldwide
societal costs of dementia in 2005”, Alzheimer's & dementia: J
Alzheimer's Association, pp. 81-91 April 2007.
2. C. Mathers, M. Leonardi, W.H.o. Global burden of dementia in
the year 2000: summary of methods and data sources. http://
www.who.int/healthinfo/statistics/bod_dementia.pdf
3. I. Grundke-Iqbal, K. Iqbal et al., “Abnormal phosphorylation of
the microtubule-associated protein tau (tau) in Alzheimer
cytoskeletal pathology”, Proc Natl Acad Sci U S A, 83(13), pp.
4913-4917 (1986).
4. N. Sergeant, A. delacourte et al., “Tau protein as a differential
biomarker for tauopathies”, Biochem Biophys Acta, 1739(2-3),
pp. 179-197 (2005).
5. C.X. Gong, I. Grundke-Iqbal et al., “dephosphorylation of
Alzheimer's disease abnormally phosphorylated tau by protein
phosphatase-2A”, Neuroscience, 61(4), pp. 765-772 (1994).
6. C.M. Wischik, P. Bentham et al., Tau aggregation inhibitor (TAI)
therapy with remberTM arrests disease progression in mild and
moderate Alzheimer's disease over 50 weeks. International
Conference on Alzheimer’s disease, Chicago 2008, http://www.
abstractsonline.com/viewer/SearchResults.asp
7. J. Leschik, A. Welzel et al., “Inverse and distinct modulation of
tau-dependent neurodegeneration by presenilin 1 and
amyloid-beta in cultured cortical neurons: evidence that tau
phosphorylation is the limiting factor in amyloid-beta-induced
cell death”, J Neurochem., 101(5), pp. 1303-13015 (2007).
8. N. Sreejayan, M.N.A. Rao, “Nitric oxide scavenging by
curcuminoids”, J Pharm Pharmacol., 49, pp. 105-107 (1997).
9. G.P. Lim, T. Chu et al., “The curry spice curcumin reduces
oxidative damage and amyloid pathology in an Alzheimer
transgenic mouse”, J Neurosci., 21, pp. 8370-8377 (2001).
10. v. Chandra, R. Pandav et al., “Incidence of Alzheimer's disease
in a rural community in India: the Indo-US study”, Neurology,
57(6), pp. 985-989 (2001).
11. S.Y. Jeon, K. Bae et al., “Green tea catechins as a BACE1 (betasecretase)
inhibitor”, Bioorg Med Chem Lett., 13(22), pp. 3905-
3908 (2003).
12. L. Gasparini, G.K. Gouras et al., “Stimulation of beta-amyloid
precursor protein trafficking by insulin reduces intraneuronal
beta-amyloid and requires mitogen-activated protein
kinase signalling”, J Neurosci., 21(8), pp. 2561-2570 (2001).
13. G.S. Watson, S. Craft, The Role of Insulin Resistance in
the Pathogenesis of Alzheimer's disease: Implications
for Treatment CNS drugs, 17(1), pp. 27-45(19) (2003).
14. W.C. Knowler, E. Barrett-Connor et al., “diabetes
Prevention Program Research Grou.: Reduction in the
incidence of type 2 diabetes with lifestyle intervention
or metformin”, NEJM, 346, pp. 393-403 (2002).
15. R.A. Cherny, J.T. Legg et al., “Aqueous dissolution of
Alzheimer's disease Abeta amyloid deposits by
biometal depletion”, J Biol Chem., 274(33), pp. 23223-
23228 (1999).
16. A.I. Bush, W.H. Pettingell et al., “Rapid induction of
Alzheimer A8 amyloid formation by zinc”,
Science, 265, pp. 1464-1465 (1994).
17. K. ono, K. Hasegawa et al., “Curcumin has
potent anti-amyloidogenic effects for Alzheimer's
beta-amyloid fibrils in vitro”, J Neurosci Res., 75(6),
pp. 742-750 (2004).
18. L. Baum, A. Ng, “Curcumin interaction with copper and
iron suggests one possible mechanism of action in
Alzheimer’s disease animal models”, J Alzheimer’s dis., 6,
pp. 367-377 (2004).
19. J. Wang, L. Ho et al., “Grape-derived Polyphenolics
Prevent A-beta oligomerization and Attenuate Cognitive
deterioration in a Mouse Model of Alzheimer's disease”, J
Neuroscience, 28, pp. 6388-6392 (2008).
20. d.A. Butterfield, A. Castegna et al., “Evidence that
amyloid beta-peptide-induced lipid peroxidation and
its sequelae in Alzheimers disease brain contribute to
neuronal death”, Neurobiol Ageing, 23(5), pp. 665-
664 (2002).
21. H. Schroeter, R.J. Williams et al., “Phenolic
antioxidants attenuate neuronal cell death following
uptake of oxidized low-density lipoprotein”, Free Radic
Biol Med., 29(12), pp.1222-1233 (2000).
22. C.A.M. McLean, R.A. Cherny et al., “Soluble pool of Abeta
amyloid as a determinant of severity of neurodegeneration in
Alzheimer's disease”, Ann. Neurol., 46, pp. 860-866(1999).
23. d.G. Smith, R. Cappai et al., “The redox chemistry of the
Alzheimer's disease amyloid beta peptide”, Biochim Biophys
Acta., 1768(8), pp. 1976-1990 (2007).
24. d.P. Naughton Personal communication, 2008.
25. A.E. Fisher, d.P. Naughton, “Therapeutic chelators for the twenty
first century: new treatments for iron and copper mediated
inflammatory and neurological disorders”, Curr drug deliv., 2(3),
pp. 261-268 (2005).
26. Rao M.N. Sreejayan, “Curcuminoids as potent inhibitors of lipid
peroxidation”, J Pharm Pharmacol., 46(12), pp. 1013-1016
(1994).
27. J. Rogers, “Inflammation as a pathogenic mechanism in
Alzheimer's disease”, Arzneimittelforschung/drug Res., 45, pp.
439-442 (1995).
28. J. Hong, M. Bose et al., “Modulation of arachidonic acid
metabolism by curcumin and related â-diketone derivatives:
effects on cytosolic phospholipase A2, cyclooxygenases, and
5-lipoxygenase”, Carcinogenesis, 20(3), pp. 445-451, March 1999
29. A. Majumdar, H. Chung et al., “degradation of fibrillar forms of
Alzheimer's amyloid beta-peptide by macrophages”, Neurobiol
Aging., 29(5), pp. 707-715 (2008).
30. F. Yang, G.P. Lim et al., “Curcumin inhibits formation of amyloid
beta oligomers and fibrils, binds plaques, and reduces amyloid
in vivo”, J Biol Chem., 280(7), pp. 5892-5901 (2005).

Läsare som vill ha en komplett referenslista kan kontakta författaren på paulrclayton@gmail.com.